Cann Group (ASX:CAN) Pretax Margin %: 583.48% (As of Dec. 2025)


What is Cann Group Pretax Margin %?

Cann Group ASX:CAN -25.00% Pretax Margin % is 583.48% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Cann Group ranks better than 99.27% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Cann Group's Pre-Tax Income for the six months ended in Dec. 2025 was A$26.38 Mil. Cann Group's Revenue for the six months ended in Dec. 2025 was A$4.52 Mil. Therefore, Cann Group's pretax margin for the quarter that ended in Dec. 2025 was 583.48%.

The historical rank and industry rank for Cann Group's Pretax Margin % or its related term are showing as below:

ASX:CAN' s Pretax Margin % Range Over the Past 10 Years
Min: -2617.77   Med: -439.09   Max: 157.49
Current: 157.49


ASX:CAN's Pretax Margin % is ranked better than
99.27% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.28 vs ASX:CAN: 157.49

Cann Group  (ASX:CAN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Cann Group Pretax Margin % Related Terms


Cann Group Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Cann Group's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cann Group Pretax Margin % Chart

Cann Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only -584.74 -412.85 -245.26 -333.32 -197.74

Cann Group Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -168.94 -535.93 -165.42 -240.99 583.48

ASX:CAN vs ZTS: Pretax Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cann Group Pretax Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cann Group's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Cann Group's Pretax Margin % falls into.



Cann Group Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Cann Group's Pretax Margin for the fiscal year that ended in Jun. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-22.345/11.3
=-197.74 %

Cann Group's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=26.379/4.521
=583.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 583.48% mean?
Cann Group (ASX:CAN) has a Pretax Margin % of 583.48% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #7 out of 955 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is Cann Group's Pretax Margin % too high?
Cann Group's current Pretax Margin % is 583.48%. The Drug Manufacturers industry median Pretax Margin % is 7.28. Cann Group's value of 583.48% is 7914.8% above this industry median. Based on the distribution chart, Cann Group ranks #7 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #7 out of 955 companies for Pretax Margin %. This places Cann Group in the top 1% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Cann Group's value of 583.48% is 7914.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current Pretax Margin % of 583.48% is 7914.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Pretax Margin % is 583.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current Pretax Margin % is 583.48% and 7914.8% above the Drug Manufacturers industry median of 7.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Pretax Margin % is 583.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cann Group Business Description

Other Exchanges CNGGF:USA
Address 262-276 Lorimer Street, Ground Floor, Port Melbourne, VIC, AUS, 3207
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.